DrugRisk Report: FDA Links 603 Deaths to Pradaxa as Lawsuits Increase

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Pradaxa Diagram
Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options.

Dallas, Texas (PRWEB) March 15, 2013

The drug safety advocates at DrugRisk.com are alerting those patients taking the blood thinner Pradaxa of information added to the site showing the FDA has related at least 603 patient deaths to the medication.

“The mission of DrugRisk is to improve consumer safety by sharing the latest warnings, recalls, studies and legal news. Patients who stay informed can discuss side effect options with their doctor and decide if they need legal advice,“ explains DrugRisk representative Ryan Mayer.

The resource center has compiled research showing experts still disagree about the risk for Pradaxa internal bleeding. While the FDA has issued an update indicating the drug has the same risks as warfarin*, the American College of Cardiology has cautioned that Pradaxa can increase the risk of bleeding complications compared to warfarin**.

DrugRisk also contains a report from the Institute for Safe Medication Practices, which studied nearly 18,000 adverse events reported to the FDA. Not only did the institute rank blood thinners like Pradaxa among the most dangerous drugs, they discovered patients with Pradaxa-related bleeding were nearly 5 times as likely to die than those with warfarin bleeding***.

Now, the resource center has learned that the FDA has listed Pradaxa as the primary suspect in the death of 603 patients in AERS adverse event reports collected from the manufacturer, Boehringer Ingelheim****.

Due to the number of patients filing a lawsuit alleging Pradaxa side effects, the cases have been consolidated to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

DrugRisk has added the latest court updates showing the number of patients filing a Pradaxa lawsuit alleging serious or fatal internal bleeding has grown from 170 on January 14 to 260 as of March 5, 2013, an increase of over 50%.*****

Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options. Due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
** http://content.onlinejacc.org/article.aspx?articleid=1206384
***Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****http://www.adverseevents.com/drugdetail.php?AEDrugID=1067
*****jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_by_District-March-5-2013.pdf


Contact